Poor
Partially Aligned
Patient Risk:
Low
Summary
Most claims are financial-assistance/discount program statements that are not supported by the provided FDA prescribing information excerpts. Only general drug composition/being prescription and broad therapeutic areas are partially aligned, while the cardiovascular-event risk reduction claim is label-supported but not the specific access/discount amounts or eligibility requirements.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing omega-3 fatty acids.
Supported by label text provided indicating VASCEPA (icosapent ethyl) is an omega-3 fatty acid ethyl ester (Section 1; and warnings mention it is obtained from fish). Prescription status and omega-3 content align with provided label context.
Vascepa is used to treat high triglycerides.
Section 1: indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Vascepa is used to reduce the risk of cardiovascular events.
Section 1 and Section 14.1: adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization; trial evidence in Section 14.1.
Unsupported Statements
Amarin offers a Vascepa Savings Card program.
No information about any savings card program is present in the provided FDA prescribing information excerpts.
The Vascepa Savings Card can provide up to $50 per prescription.
No program benefit amounts are described in the provided FDA prescribing information excerpts.
The Vascepa Savings Card has a maximum savings of $300 per year.
No program benefit limits are described in the provided FDA prescribing information excerpts.
To be eligible for the Vascepa Savings Card, patients must have a valid prescription.
No savings-card eligibility criteria are described in the provided FDA prescribing information excerpts.
To be eligible for the Vascepa Savings Card, patients must be 18 years or older.
No savings-card eligibility criteria (age) are described in the provided FDA prescribing information excerpts.
To be eligible for the Vascepa Savings Card, patients must have a valid government-issued ID.
No savings-card eligibility criteria (ID) are described in the provided FDA prescribing information excerpts.
Amarin offers a patient assistance program (PAP) that provides free or reduced-cost Vascepa to eligible patients.
No patient assistance program details are described in the provided FDA prescribing information excerpts.
The Amarin patient assistance program is available to patients who meet certain income and insurance requirements.
No PAP eligibility criteria are described in the provided FDA prescribing information excerpts.
Patients can apply for the Amarin patient assistance program through the Amarin website or by contacting their healthcare provider.
No application pathways are described in the provided FDA prescribing information excerpts.
Many insurance plans, including Medicare Part D and Medicaid, cover Vascepa.
No payer coverage statements are included in the provided FDA prescribing information excerpts.
The level of coverage and copayment requirements for Vascepa can vary depending on the insurance plan.
No insurance/cost variability statements are included in the provided FDA prescribing information excerpts.
Express Scripts offers a discount program for Vascepa.
No third-party discount program information is included in the provided FDA prescribing information excerpts.
Some online discount programs and coupon websites offer discounts on Vascepa.
No discount/coupon website statements are included in the provided FDA prescribing information excerpts.
DrugPatentWatch.com reports that there are currently several online discount programs available for Vascepa, including a $25 discount coupon.
No external website or specific coupon amount is discussed in the provided FDA prescribing information excerpts.
GoodRx offers discounts on Vascepa.
No discount marketplace information is included in the provided FDA prescribing information excerpts.
RxSaver offers discounts on Vascepa.
No discount marketplace information is included in the provided FDA prescribing information excerpts.
Online pharmacies such as GoodRx and RxSaver often have lower prices than traditional pharmacies.
No pricing comparisons are included in the provided FDA prescribing information excerpts.
Online pharmacies such as GoodRx and RxSaver may offer additional discounts or coupons.
No discount/coupon marketplace statements are included in the provided FDA prescribing information excerpts.
Medicaid can provide financial assistance for Vascepa.
No Medicaid assistance statements are included in the provided FDA prescribing information excerpts.
Patients who are eligible for Medicaid may be able to receive free or reduced-cost Vascepa.
No Medicaid assistance/free-or-reduced-cost statements are included in the provided FDA prescribing information excerpts.
Medicare can provide financial assistance for Vascepa.
No Medicare assistance statements are included in the provided FDA prescribing information excerpts.
Patients who are eligible for Medicare may be able to receive free or reduced-cost Vascepa.
No Medicare assistance/free-or-reduced-cost statements are included in the provided FDA prescribing information excerpts.
The Veterans Administration (VA) may provide financial assistance for Vascepa.
No VA assistance statements are included in the provided FDA prescribing information excerpts.
Eligible veterans can contact their VA healthcare provider to determine their eligibility for Vascepa financial assistance.
No VA assistance guidance is included in the provided FDA prescribing information excerpts.
The Patient Access Network Foundation offers financial assistance for Vascepa.
No foundation assistance program information is included in the provided FDA prescribing information excerpts.
The HealthWell Foundation offers financial assistance for Vascepa.
No foundation assistance program information is included in the provided FDA prescribing information excerpts.
Patient Access Network Foundation and HealthWell Foundation provide grants to patients who meet certain income and insurance requirements.
No foundation-specific eligibility criteria are included in the provided FDA prescribing information excerpts.
Some pharmaceutical companies, including Amarin, offer financial assistance to patients who are unable to afford their medication.
No general or company-specific financial assistance statements are included in the provided FDA prescribing information excerpts.
Patients can contact Amarin directly to inquire about available assistance programs.
No assistance program contact instructions are included in the provided FDA prescribing information excerpts.
The average retail price of Vascepa is around $250 per prescription.
No pricing information is included in the provided FDA prescribing information excerpts.
DrugPatentWatch.com reports the average retail price of Vascepa is around $250 per prescription.
No external pricing reporting is included in the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
No reviewable FDA label content was provided for any dosage, contraindications, warnings/precautions, drug interactions, adverse reactions, or administration instructions in the claims list (i.e., the claims focus on discounts/access rather than label safety information).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about discounts/financial assistance and do not directly introduce FDA-label dosing or safety misinformation. However, lack of label-aligned safety/access guidance could indirectly affect safe use if relied upon instead of prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Most claims are about savings cards, patient assistance programs, and discount/pricing/cost coverage, which are not addressed in the provided FDA label excerpts.
Suggested Improvement
Limit claims to those explicitly supported by the provided label text (e.g., indications, general omega-3/active ingredient, and labeled safety/administration statements). Remove or reframe financial/discount and payer-coverage statements unless the FDA label excerpt provided includes them.